All News

Welcome to the latest public health emergency: Shortages of anti-infective agents. These shortages can adversely affect clinical care and patient outcomes according to a new study.

A combination of vitamin D and calcium supplementation can reduce the risk of fractures in older adults, according to a study published in the December 20, 2011, issue of the Annals of Internal Medicine.

Two pharmacy organizations issued a report aimed at helping colleges and schools of pharmacy develop medication therapy management curricula. The study also emphasized the importance of students learning these lessons early.

Two leading pharmacy groups are combining forces on an initiative that they hope will more effectively involve pharmacists in the coordination of care transition and reduce the number of hospital readmissions of patients

FDA approved the first generic version of the cholesterol-lowering drug Lipitor (atorvastatin calcium tablets).

FDA is requiring that manufacturers of tumor necrosis factor blockers perform enhanced safety surveillance in children, teenagers, and young adults, the agency said on November 3 in an ongoing safety review of this class of biologic products.

Political mavens James Carville and Marlee Matlin will be the keynote speakers at this year’s American Society of Health Systems Pharmacists’ Midyear Clinical Meeting.

Some essential chemotherapy drugs are in short supply for the first time in the United States, according to the October 3 New England Journal of Medicine.

The American Heart Association and American College of Cardiology Foundation have issued new guidelines for secondary prevention and risk reduction in patients with atherosclerotic vascular disease.

The Centers for Disease Control and Prevention recently launched a new antibiotic tracking system, allowing hospitals to monitor their antibiotic use electronically.

FDA approved zolpidem tartrate sublingual tablets (Intermezzo, Transcept Pharmaceuticals) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

Pharmacy association veteran Kathleen Jaeger will publicly advance the role of pharmacists in patient care in a newly created position with the National Association of Chain Drug Stores.

Pfizer, Medco, and pharmacy groups are all battling to get their voices heard after a November The New York Times article raised questions about prescribing Lipitor versus Atorvastatin (the new generic form of Lipitor).

Patients using the relatively new blood thinner dabigatran (Pradaxa, Boehringer Ingelheim) failed to remain on the treatment 17% of the time after the first 4 months, increasing their risk of stroke, according to a new study.

Pharmacy and medical groups are suing the California Department of Health Care Services and the U.S. Department of Health and Human Services over the Centers for Medicare and Medicaid Services’ recent approval of a 10% reimbursement rate cut in California’s Medicaid program.

The American Heart Association and American College of Cardiology Foundation have issued new guidelines for secondary prevention and risk reduction in patients with atherosclerotic vascular disease.

FDA has appealed the September 2011 ruling made by the U.S. District Court for the Middle District of Florida in U.S. v. Franck’s Lab, Inc. The ruling had favored pharmacy compounding for veterinary patients.

FDA has approved aflibercept (Eylea Injection, Regeneron), known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) age-related macular degeneration in patients aged 60 and older at a recommended dose of 2 mg every 4 weeks (monthly) for the first 12 weeks, followed by 2 mg every 8 weeks (2 months).

FDA approved ruxolitinib (Jakafi, Incyte) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.

FDA Commissioner Margaret A. Hamburg, MD, announced the agency's decision to revoke the breast cancer indication for bevacizumab (Avastin), noting that the benefits do not outweigh the potentially life-threatening side effects, such as heart attack or heart failure, high blood pressure, bleeding and hemorrhaging, and the development of perforations in different parts of the body, such as the nose, stomach, and intestines.

The NACDS lauded the U.S. Senate’s vote last week to defeat an amendment that would have allowed “personal importation” of prescription medications from Canada.

FDA has approved bupivacaine hydrochloride injection, USP (Sagent and Strides Arcolab), a local or regional anesthetic, for use in surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.

In this section we showcase products and product news that ran up against space limitations or fell outside the parameters of recently featured categories in the print edition.

Children who are overweight or obese have 3 times as much risk of high blood pressure as children of normal weight have, reported a study published recently in Hypertension: Journal of the American Heart Association.

Community pharmacists? opposition to the proposed Express Scripts/Medco Health Solutions merger was heard loud and clear during NCPA?s annual convention held last week in Nashville, Tenn.

Purdue Pharma and the NCPA premiered the third annual ?RxPATROL Pharmacy Safety and Security? video last week at NCPA?s annual convention in Nashville, Tenn.

Medicare Part B patients will suffer if diabetes testing supplies are subjected to competitive bidding prices, concluded a recent NCPA survey of more than 800 independent pharmacists.

Vivus has resubmitted its New Drug Application (NDA) for Qnexa (phentermine/topiramate) to FDA.